anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to an oral quick release preparation of indinavir and a preparing method thereof. The oral quick release preparation of indinavir is used for treating acquired immune deficiency syndrome, the oral quick release preparation of indinavir can be quickly disintegrated and released, and the oral quick release preparation of indinavir can shield bad taste. The oral quick release preparation of indinavir can exist in a mode of an oral disintegrating tablet, a dispersive tablet and an oral solution tablet. The oral quick release preparation of indinavir contains 0.1 to 95% of indinavir and 5 to 99.9% of medicinal auxiliary material according to the weight percentage. The oral quick release preparation of indinavir, which is prepared according to the present invention, extends the preparation range of indinavir. The formulation is reasonable; the disintegrating property is good; when a person takes the oral quick release preparation of indinavir, no sand sensation occurs, and the person can not feel discomfortable; the preparation technology is simple and convenient. Dispersive tablets, oral quick solution tablets or oral disintegrating tablets which have high quality can be economically and conveniently prepared in a mass preparation mode by conventional equipment for preparing tablets in pharmaceutical industry. The absorption rate is high, the biological availability and the blood medicine concentration of medicine can be enhanced, and therefore, the therapeutic effect for resisting HIV viruses can be improved. The preparation can be conveniently taken, and the mouth feel is good. The preparation can be quickly disintegrated in the oral cavity when encountering sputum. The preparation provides convenience for old people, children or patients who have the obstacle in swallowing medicine, or can not conveniently take water.
BACKGROUND AND OBJECTIVE: Autosomal recessive genetic disorders pose significant health challenges in regions where consanguineous marriages are prevalent. The utilization of exome sequencing as a frequently employed methodology has enabled a clear delineation of diagnostic efficacy and mode of inheritance within multiplex consanguineous families. However, these aspects remain less elucidated within simplex families.
METHODS: In this study involving 12 unrelated simplex Iranian families presenting syndromic autism, we conducted singleton exome sequencing. The identified genetic variants were validated using Sanger sequencing, and for the missense variants in FOXG1 and DMD, 3D protein structure modeling was carried out to substantiate their pathogenicity. To examine the expression patterns of the candidate genes in the fetal brain, adult brain, and muscle, RT-qPCR was employed.
RESULTS: In four families, we detected an autosomal dominant gene (FOXG1), an autosomal recessive gene (CHKB), and two X-linked autism genes (IQSEC2 and DMD), indicating diverse inheritance patterns. In the remaining eight families, we were unable to identify any disease-associated genes. As a result, our variant detection rate stood at 33.3% (4/12), surpassing rates reported in similar studies of smaller cohorts. Among the four newly identified coding variants, three are de novo (heterozygous variant p.Trp546Ter in IQSEC2, heterozygous variant p.Ala188Glu in FOXG1, and hemizygous variant p.Leu211Met in DMD), while the homozygous variant p.Glu128Ter in CHKB was inherited from both healthy heterozygous parents. 3D protein structure modeling was carried out for the missense variants in FOXG1 and DMD, which predicted steric hindrance and spatial inhibition, respectively, supporting the pathogenicity of these human mutants. Additionally, the nonsense variant in CHKB is anticipated to influence its dimerization - crucial for choline kinase function - and the nonsense variant in IQSEC2 is predicted to eliminate three functional domains. Consequently, these distinct variants found in four unrelated individuals with autism are likely indicative of loss-of-function mutations.
CONCLUSIONS: In our two syndromic autism families, we discovered variants in two muscular dystrophy genes, DMD and CHKB. Given that DMD and CHKB are recognized for their participation in the non-cognitive manifestations of muscular dystrophy, it indicates that some genes transcend the boundary of apparently unrelated clinical categories, thereby establishing a novel connection between ASD and muscular dystrophy. Our findings also shed light on the complex inheritance patterns observed in Iranian consanguineous simplex families and emphasize the connection between autism spectrum disorder and muscular dystrophy. This underscores a likely genetic convergence between neurodevelopmental and neuromuscular disorders.
PROBLEM TO BE SOLVED: To obtain a treating agent capable of alleviating panic disorder specifically consisting of panic attack, agoraphobia or phobic anxiety by compounding a specific compound known as an antidepressant as an active component. SOLUTION: This agent is composed of nefazodone of the formula, i.e., 2- 3-[4(3-chlorophenyl)-1piperazinyl]propyl}-5ethyl-2,4-dihydro-4-(2pheno xyethyl)-3 H-1, 2,4-triazol-3-one or its pharmaceutically permissible acid-addition salt. Nefazodone hydrochloric acid salt is preferably administered orally as a treating agent. An appropriate daily dose for an adult patient is 200-600mg. Especially, the daily dose is preferably divided into two doses. Nefazodone can extremely improve a panic state by means of serotonergic transmission and dual effect on norepinephrine uptake.
BACKGROUND: Multiplex syndromic gastrointestinal panels (GIPCR) have streamlined the diagnosis of infectious diarrhea. Additionally, they have expanded the number of pathogens that can be routinely evaluated, allowing further understanding of the prevalence of enteric pathogens in various patient populations. The goal of this study was to investigate the prevalence and clinical presentation of astrovirus and sapovirus gastroenteritis in adult oncology patients as detected by the FilmArray GIPCR.
METHODS: All GIPCR panel results from December 2017 to June 2021 were retrospectively reviewed to determine the prevalence of astrovirus and sapovirus in adult oncology patients. Medical records were also reviewed to obtain clinical information. Repeat GIPCR positivity and symptom duration were used to estimate prolonged viral shedding.
RESULTS: A total of 18,014 panels were performed on samples collected from 9303 adults. Overall, astrovirus and sapovirus were detected in 0.35% (33/9303) and 0.45% (42/9303) GIPCRs respectively. At least one viral target was detected in 424 (4.4%) patients. Astrovirus accounted for 7.8% (33/424) and sapovirus 9.9% (42/424) of patients. Diarrhea was the most common symptom documented. A subset of transplant patients had protracted viral detection with a median of ~27 days (range 23-43 days) for astrovirus and 97 days (range 11-495) for sapovirus. No clusters or outbreaks were identified during the study period.
CONCLUSION: In oncology patients with viral gastroenteritis, astrovirus and sapovirus were the causative agents in 18% of the cases. Both viruses were associated with mild disease. Prolonged diarrhea and viral shedding were observed in a few transplant patients.
PURPOSE: (1) To report the clinical and radiological outcomes of a surgical technique combining anatomic medial patellofemoral ligament reconstruction and tibia tuberosity transfer in adolescents with patella alta and elevated tibial tuberosity-trochlear groove (TT-TG) distance in the treatment of recurrent patellar dislocation; and (2) to investigate the potential risks of growth arrest or developmental deformities associated with this combined technique.
METHODS: Medical records of patients who underwent the combined surgery from 2015 to 2019 were reviewed. This study included adolescents aged between 14 and 18 years with a Caton-Deschamps index (CDI) > 1.30 and TT-TG distance >20 mm, with a minimum follow-up of 4 years. Radiological examinations including lateral views and full-length posteroanterior standing radiographs were investigated to assess patella height by CDI, posterior tibial slope (PTS) angle, side-to-side difference in bone length, and lower extremity alignment by hip-knee-ankle angle; computed tomography scans and magnetic resonance imaging profiles were investigated to evaluate TT-TG distance and staging of growth plate closure. Other evaluations included preoperative and postoperative physical examination, Kujala score, and Tegner activity score. The patients were stratified into 3 subgroups according to an magnetic resonance imaging-based staging system of the growth plate closure, and each outcome was analyzed. A cohort-specific minimal clinically important difference estimation was performed using standard error of measurement.
RESULTS: The average age at the time of surgery was 16.1 years (range, 14.1-17.8). The average follow-up was 5.6 years (range, 4.0-7.6). No recurrent dislocation occurred, and no clinically significant deformity or axis deviation was encountered. Postoperative patellar height by CDI was 1.00 ± 0.11 (range, 0.81-1.15). No significant differences were found in the preoperative and postoperative hip-knee-ankle angle or side-to-side difference in femur/tibia length among all subgroups. A significantly decreased PTS angle was found in patients with open growth plates, from 10.2° ± 1.7° before surgery to 8.1° ± 1.0° after surgery (P = .015). The Kujala score and Tegner score both significantly improved, from 65.5 ± 13.9 before surgery to 90.4 ± 7.2 after surgery in the Kujala score (P < .001) and from 4.0 ± 1.1 before surgery to 4.7 ± 1.3 after surgery in the Tegner score (P < .001). Of the whole cohort, 63.1%, 100%, 47.1%, and 94.1% of patients achieved the minimal clinically important difference for PTS angle, CDI, Tegner score, and Kujala score, respectively.
CONCLUSIONS: This combined technique is safe and effective in treating recurrent patellar dislocation in skeletally mature adolescents with concurrent patella alta (CDI > 1.30) and TT-TG distance >20 mm, permitting patients to have improved knee function and low complication rates. Nonetheless, patients with open growth plates demonstrated a decrease in PTS, which might predispose the knee to recurvatum and osteoarthritis in the long term.
LEVEL OF EVIDENCE: Level IV, controlled case series.
Saussurea Involucrata Liquid Tonic 20ml/time, 2 times a day, orally on an empty stomach. Total treatments 8 weeks, followed up to 12 weeks.
Patients in the ESWT group will be treated with ESWT once a week for 4 weeks. Each patient was treated with epine calcaneus and its surroundings. The treatment dose of 10 Hz, 2.5 bar, 2000 shock wave with BTL L-6000 SWT device will be applied by the same therapist. Patient completed plantar fascia and gastrocnemius streching exercises right after treatment. The patient completed the plantar fascia and gastrocnemius stretching exercises right after treatment and also continue at home for 4 weeks, 2 sets per day. Completed 3 repetation for each exercise and stayed in the same position for 30 seconds.
FIELD: medicine.SUBSTANCE: group of inventions relates to medicine, specifically to oncology, and can be used in a subject to treat a brain tumour that has blood vessels with holes in its walls. To this end, a therapeutically effective amount of a composition consisting of intact bacterially derived minicells having a diameter of 400 nm ± 50 nm is systemically administered to a subject with a tumour. Each minicell contains an antibody that specifically recognises the antigen of tumour cells. Each minicell contains an antineoplastic agent. Minicells passively pass through openings in the walls of blood vessels. Also disclosed is use a composition containing said minicells to prepare a medicament for treating a brain tumour.EFFECT: group of inventions provides treatment of brain tumours by accumulation of minicells containing an antineoplastic agent, in the microenvironment of the brain tumour and the delivery of the antineoplastic agent directly to the tumour cells, without endothelial endocytosis/transcytosis through the blood-brain barrier.44 cl, 2 tbl, 13 dwg, 10 ex
PROBLEM TO BE SOLVED: To obtain a cosmetic excellent in adhesion to the skin, feeling of use such as slippery feeling and adsorbability for sweat, sebum or the like by including a powder obtained through subjecting shellfish shell to firing and crushing treatments. SOLUTION: This cosmetic is obtained by including a powder obtained through subjecting shellfish shell to firing and crushing treatments. As for the shellfish, any shellfish such as univalve, bivalve, and spiral one, for instance, short-necked clam, corbicula, hard clam oyster, turban shell, Spisura sachalinensis, scallop, and constricted tagelus, can be used. The firing temperature is preferably 200-1,000 deg.C, more preferably 500-800 deg.C. The firing time is preferably 1-7 day. The crushing treatment is to be continued until the mean particle diameter of the final powder becomes preferably about 0.1-100 mμ, more preferably 1-50 mμ. It is preferable that the firing treatment is done first followed by the crushing treatment. The content of the power in the cosmetic is preferably 0.1-50 wt.%, more preferably 1-40 wt.%.
INTRODUCTION: severe abdominal sepsis, accompained by diffuse peritonitis, poses a significant challenge for most surgeons. It often requires repetitive surgical interventions, leading to complications and resulting in high morbidity and mortality rates. The open abdomen technique, facilitated by applying a negative-pressure wound therapy (NPWT), reduces the duration of the initial surgical procedure, minimizes the accumulation of secretions and inflammatory mediators in the abdominal cavity and lowers the risk of abdominal compartment syndrome and its associated complications. Another approach is primary closure of the abdominal aponeurosis, which involves suturing the layers of the abdominal wall.
METHODS: the objective of this study is to conduct a survival analysis comparing the treatment of severe abdominal sepsis using open abdomen technique versus primary closure after laparotomy in a public hospital in the South of Brazil. We utilized data extracted from electronic medical records to perform both descriptive and survival analysis, employing the Kaplan-Meier curve and a log-rank test.
RESULTS: the study sample encompassed 75 laparotomies conducted over a span of 5 years, with 40 cases employing NPWT and 35 cases utilizing primary closure. The overall mortality rate observed was 55%. Notably, survival rates did not exhibit statistical significance when comparing the two methods, even after stratifying the data into separate analysis groups for each technique.
CONCLUSION: recent publications on this subject have reported some favorable outcomes associated with the open abdomen technique underscoring the pressing need for a standardized approach to managing patients with severe, complicated abdominal sepsis.
The invention relates to a pH responsive thrombolytic drug targeting nanogel, a synthesis method and application thereof. The nanogel is formed by covalent linkage of a thrombolytic drug and oxidative dextran through a pH sensitive imine linkage and introduction of a thrombus-targeted ligand to an oxidative dextran molecular chain. The imine linkage is stable under normal physiological pH value, and can hydrolyze under a weak acid pH value. The thrombus-targeted ligand enables the nanogel with thrombus active targeting ability, is stable in a circulation system, and releases drug molecules after reaching an embolism part, thus reducing the risk of body bleeding caused by the thrombolytic drug. The nanogel has reversible biological properties. By regulating the molecular weight, reaction ratio and functional group of the polymer, the hydrolysis resistant degree and opportunity of thrombolytic drug protein molecules to hydrolase can be regulated, and also activity release to drug molecules can be controlled. The microsystem can be used as a thrombolytic drug carrier for transportation of protein or peptide drugs so as to realize synergistic treatment of drugs.
PURPOSE: In case of soft tissue sarcomas (STS), an en-bloc resection with safe margins is recommended. To ensure safe removal without tumor rupture, STS of the groin area, retroperitoneal or pelvic mesenchymal tumors may require incision or resection of the inguinal ligament. Solid reconstruction is mandatory to prevent early and late postoperative femoral hernias. We present here a new technique of inguinal ligament reconstruction.
METHODS: Between September 2020 and September 2022, patients undergoing incision and/or resection of inguinal ligaments during a wide en-bloc resection of STS of the groin area in the Department of General Surgery in Strasbourg were included. All patients had an inguinal ligament reconstruction with biosynthetic slowly resorbable mesh shaped as a hammock, pre- or intraperitoneally, associated or not with loco-regional pedicled muscular flaps.
RESULTS: A total of 7 hammock mesh reconstructions were performed. One or several flaps were necessary in 57% of cases (4 patients): either for inguinal ligament reconstruction only (n = 1), for recovering of femoral vessels (n = 1), and for both ligament reconstruction and defect covering (n = 2). The major morbidity rate was 14.3% (n = 1), related to a thigh surgical site infection due to sartorius flap infarction. After a median follow-up of 17.8 months (range 7-31), there was neither early nor late occurrence of post-operative femoral hernia.
CONCLUSIONS: This is a new surgical tool for inguinal ligament reconstruction with the implementation of a biosynthetic slowly resorbable mesh shaped as a hammock, which should be compared to other techniques.
PURPOSE: A composition containing garlic extract is provided to suppress tumor cell migration and to ensure stability without side effects. CONSTITUTION: A composition for suppressing tumor cell migration contains garlic extract as an active ingredient. The extract is obtained using butanol. The garlic extract is also butanol fraction extract obtained by fractioning methanol extract with hexane, chloroform, and butanol in order. The composition is a pharmaceutical composition or health food composition. The pharmaceutical composition further contains carrier, excipient, and diluent. The health food composition is manufactured in the form of foods, beverage, gum, tea, and vitamin complex.
Double-blind studies suggest that olanzapine is highly effective for the treatment of individuals with bipolar disorder. However, weight gain and impaired glucose tolerance remain significant concerns associated with olanzapine. Exenatide is an anti-diabetic medication that is associated with weight loss and improved glucose regulation. Therefore, the overall goal of the proposed study is to conduct a 16-week double-blind placebo-controlled study of exenatide for the treatment of weight gain associated with olanzapine in 60 obese adults with bipolar disorder treated with olanzapine. We propose to conduct the study over the course of 24 months, with an expected enrollment of approximately 3 patients per month. The primary outcome measure will be change from baseline to endpoint in weight. The secondary outcome measures will include changes from baseline to endpoint, in body mass index (BMI), abdominal circumference, metabolic parameters, clinical global improvement of psychiatric symptoms, and change in manic, depressive and psychotic symptoms. Rates of adverse events also will be assessed.
Candesartan Cilexetil 

The volume of distribution of candesartan is 0.13 L/kg. Candesartan is highly bound to plasma proteins (>99%) and does not penetrate red blood cells. The protein binding is constant at candesartan plasma concentrations well above the range achieved with recommended doses. In rats, it has been demonstrated that candesartan crosses the blood-brain barrier poorly, if at all. It has also been demonstrated in rats that candesartan passes across the placental barrier and is distributed in the fetus.

Hydrochlorothiazide 

Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.
The vBlocT2D study is a two arm, randomized, controlled, unblinded clinical trial in which 60 adult patients with T2D with moderate to extreme obesity (BMI 35-45 kg/m2) and suboptimal glycemic control (glycated haemoglobin (HbA1c) 7-10%) without significant diabetic complications, will be randomized to usual care alone (n=30) or vBloc therapy plus usual care (n=30) to assess the superiority of vBloc therapy plus usual care than standard usual care alone in improving diabetic control. The vBloc therapy will be delivered through an electrical and reversible vagal blocking device (the Maestro Rechargeable System) implanted using laparoscopic surgery. The device was approved by the FDA in 2015 for weight loss in adults with BMI 40-45 kg/m2, or BMI 35-39.9 kg/m2 with one or more obesity-related co-morbid conditions. The study will recruit patients over a 12-month period and follow each individual for 12-months post intervention. The primary outcome is change in HbA1c at 12-months post randomization. The secondary outcomes are changes in weight, waist and hip circumferences, blood pressure, lipids, insulin sensitivity and β-cell health measured through oral glucose tolerance testing, dietary intake, eating behaviors, physical activity, quality of life and potential circulating biomarkers. Medication use, clinical labs and adverse events will be compared as well.
Patients receive doxorubicin hydrochloride, cyclophosphamide, and paclitaxel as in arm I. Patients then receive trastuzumab (Herceptin®) IV over 30-90 minutes beginning on day 1 of week 25 and continuing weekly for 52 courses in the absence of disease progression or unacceptable toxicity. Within 5 weeks after completion of paclitaxel, patients may undergo radiotherapy. All postmenopausal ER- or PR-positive patients receive oral tamoxifen or an aromatase inhibitor once daily for 5 years beginning no later than 5 weeks after the last dose of paclitaxel. Patients may also receive an aromatase inhibitor once daily for 5 years after 5 years of daily tamoxifen. Patients who receive tamoxifen once daily for less than 4.5 years may receive an aromatase inhibitor daily until they have received a total of 5 years of adjuvant hormonal therapy.
The metabolic profile during prolactinoma may be subject to significant changes. We aimed to describe the different metabolic aspects in patients monitored for prolactinoma and to study the correlations between the size of the prolactinoma and the metabolic parameters. We conducted a retrospective, descriptive, and analytical study of 77 cases of prolactinomas collected and monitored at the endocrinology and diabetology department of the Hedi Chaker Hospital in Sfax between 2000 and 2017. Our patients were divided into three groups according to the size of their prolactinomas. Statistical correlations were sought between tumor size and clinical and biological parameters. The mean age of our patients was 38.3 ± 14.2 years. They were divided into 51 women (66.2%) and 26 men (33.7%). Pituitary tumor syndrome was the most common circumstance of discovery in our population (62.3%). The clinical examination revealed an average waist circumference of 95.71 cm. Android fat distribution was observed in 25 women (49%) and 12 men (46.1%). A statistically significant positive correlation was objectified between waist circumference and tumor size (r = 0.29 and P = 0.019). The average body mass index was 28.08 kg/m2. Obesity was noted in 56 cases (72.7%). Glucose tolerance disorders and hypertriglyceridemia were also more evident each time prolactinoma size increased in contrast to the level of high-density lipoprotein cholesterol which decreased with adenoma size. Our study highlighted the metabolic and hormonal repercussions of prolactinomas. Metabolic syndrome was more common in patients with larger prolactinoma. These results should guide the initial assessment and therapeutic management of prolactin adenomas.